Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Clinical trial NCT05971758 · RECRUITING
Trial details
- NCT number
- NCT05971758
- Sponsor
- University of California, Los Angeles
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-16
- Primary completion
- 2029-01-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.